Core Viewpoint - The medical services sector experienced a decline of 0.68% on November 11, with Haoyuan Pharmaceutical leading the drop. The Shanghai Composite Index closed at 4002.76, down 0.39%, while the Shenzhen Component Index closed at 13289.0, down 1.03% [1]. Group 1: Market Performance - The medical services sector saw significant individual stock movements, with Yinosh rising by 10.46% to a closing price of 50.15, while Haoyuan Pharmaceutical fell by 2.95% to 75.40 [1][2]. - The trading volume for Yinosh was 33,400 hands, resulting in a transaction amount of 163 million yuan, while Haoyuan Pharmaceutical had a trading volume of 21,800 hands and a transaction amount of 166 million yuan [1][2]. Group 2: Capital Flow - The medical services sector experienced a net outflow of 746 million yuan from institutional investors, while retail investors saw a net inflow of 562 million yuan [2]. - The capital flow data indicates that Sunshine Nuohe had a net outflow of 37.39 million yuan from institutional investors, while Meidi Xi saw a net inflow of 28.62 million yuan [3].

Core Viewpoint - The company announced that its subsidiary, Bole Brain Machine, has recently launched the "Cyberlink AC5" product, which is expected to impact future company performance [2] Group 1 - The "Cyberlink AC5" has been officially launched [2] - Investors can find more details about the product through Bole Brain Machine's WeChat public account [2]

Group 1 - The core point of the article is that Innovation Medical has confirmed its ownership stake in Bole Brain Machine to be 68.356% as of September 2025, despite the lack of detailed disclosure regarding the subscribed capital amount [2]. - Investors have inquired about the potential acquisition plans for Bole Brain Machine, indicating interest in the company's future strategies [2]. - The confirmation of the shareholding percentage was made on November 10, highlighting the company's transparency in investor communications [2].

Core Viewpoint - Innovation Medical's stock has experienced significant volatility, with a year-to-date increase of 184.67% but a recent decline of 13.18% over the past five trading days [1] Group 1: Stock Performance - As of November 10, Innovation Medical's stock price was 22.66 CNY per share, with a market capitalization of 10 billion CNY [1] - The stock has seen a trading volume of 315 million CNY and a turnover rate of 3.28% [1] - Year-to-date, the stock has been on the leaderboard 19 times, with the most recent net purchase of 242 million CNY on October 20 [1] Group 2: Financial Performance - For the period from January to September 2025, Innovation Medical reported a revenue of 597 million CNY, a year-on-year decrease of 2.11% [2] - The net profit attributable to the parent company was 4.72 million CNY, reflecting a year-on-year increase of 116.97% [2] Group 3: Shareholder Information - As of September 30, the number of shareholders increased to 130,200, a rise of 58.75% from the previous period [2] - The average number of circulating shares per shareholder decreased by 37.01% to 3,196 shares [2] Group 4: Dividend Information - Since its A-share listing, Innovation Medical has distributed a total of 55.87 million CNY in dividends, with no dividends paid in the last three years [3]

Core Viewpoint - Shenzhen Core Medical Technology Co., Ltd. has had its IPO application accepted by the Shanghai Stock Exchange, marking it as the first innovative medical device company to be accepted under the new listing standards of the Sci-Tech Innovation Board [1] Company Overview - Core Medical specializes in the research, development, production, and sales of high-end medical devices in the field of artificial hearts and is recognized as a national high-tech enterprise [1] - The company has received investments from reputable institutional investors such as Hillhouse Capital and Zhengxin Valley [1] Product Development - Core Medical has innovatively applied "time-sharing zoned dynamic axial full magnetic suspension control technology" and "axial magnetic flux multi-drive motor technology" to the field of artificial hearts [1] - The company has developed 5 implantable and 6 interventional artificial heart products, addressing clinical needs from long-term to short-term support and from left heart to dual heart support, as well as from pediatric to adult support [1] - Several core products have entered China's special review process for innovative medical devices, with the number of products ranked first in the artificial heart field in China [1] Market Position - The Corheart® 6, launched in June 2023, is the smallest and lightest commercialized magnetic suspension implantable artificial heart globally, with a projected market share exceeding 45% in 2024 and cumulative implantations surpassing 1,000 [2] - The DuoCor® 2 is expected to be the world's first integrated magnetic suspension dual heart assist system, designed to address the long-term treatment challenges of "total heart failure" [2] - The interventional artificial heart series CorVad® 4.0/6.0 is currently in the registration approval stage and is anticipated to become the first approved interventional artificial heart product in China [2]

Group 1: New Stock Offerings - Two new stocks are available for subscription: Hengkun New Materials with a subscription code of 787727 and an issue price of 14.99 yuan per share, with a subscription limit of 10,500 shares; and Southern Network Digital with a subscription code of 301638 and an issue price of 5.69 yuan per share, with a subscription limit of 47,500 shares [2] Group 2: Economic Planning and Development - The State Council approved the "Chengdu-Chongqing Economic Circle Land Space Planning (2021-2035)", agreeing to the review by the Ministry of Natural Resources. By 2035, the arable land in the Chengdu-Chongqing Economic Circle is required to be no less than 74.1758 million acres, with permanent basic farmland protection area not less than 63.2778 million acres, and ecological protection red line area not less than 15,800 square kilometers [2] Group 3: Foreign Investment and Trade - During the China International Import Expo, the Vice Minister of Commerce expressed that China is willing to enhance communication and cooperation with all parties, continuously optimize licensing processes, and promote compliance trade for export control items [3] Group 4: MSCI Index Adjustments - MSCI announced the results of its index review for November 2025, with 69 stocks being added and 64 stocks being removed from the global standard index. Specifically, 26 Chinese stocks will be added to the MSCI China Index, while 20 will be removed [3] Group 5: Company News - Huahong Semiconductor reported a record high in third-quarter sales revenue, with a year-on-year increase of 20.7% [4] - Zhongjian Technology signed a procurement contract worth 563 million yuan, accounting for 69.34% of its main business revenue in the most recent accounting year [4] - Baiyi Shenzhou expects its operating revenue for 2025 to be between 36.2 billion yuan and 38.1 billion yuan [7]

Core Insights - Johnson & Johnson Medical Technology launched the ETHICON 4000, the first 3D stapler for laparoscopic surgery in Asia, aimed at enhancing patient outcomes by improving tissue integrity during surgical procedures [1] - The CEREGLIDE 71 distal access catheter made its Asian debut, designed for neurovascular systems, which can reach critical areas in the brain, thus providing timely intervention for stroke patients [2] - The strong and flexible blood flow-directed mesh stent, developed in collaboration with a domestic medical innovation company, was also introduced, showcasing advancements in neurointerventional devices [2] Group 1 - The ETHICON 4000 laparoscopic stapler represents a significant technological advancement, transitioning from 2D to 3D stapling, which enhances the integrity of tissue connections and reduces the risk of complications such as blood leakage [1] - The innovative pre-set chip technology in the ETHICON 4000 allows for dynamic adjustment during the stapling process, potentially decreasing postoperative complications and improving patient recovery [1] Group 2 - The CEREGLIDE 71 distal access catheter is capable of reaching the M1-M2 segments of the brain, facilitating rapid access for stroke treatment, which is critical for patient outcomes [2] - The introduction of a complete thrombectomy product line, including the EMBOTRAP III and EMBOVAC devices, highlights Johnson & Johnson's commitment to advancing neurointerventional solutions [2] - The collaboration with a domestic company to develop the blood flow-directed stent emphasizes the trend of partnerships in the medical technology sector to enhance product offerings and address specific clinical needs [2]

Core Viewpoint - The Shanghai Stock Exchange has accepted the IPO application of Shenzhen Core Medical Technology Co., Ltd., marking it as the first innovative medical device company to be accepted under the newly restarted fifth set of listing standards [1][4]. Group 1: Company Overview - Core Medical is focused on providing artificial heart products and has developed 5 implantable and 6 interventional artificial heart products, with one implantable product already commercialized and two interventional products in the registration approval stage [3]. - The company's first commercialized product, the Corheart6, is the smallest and lightest magnetic levitation implantable artificial heart globally, with the highest cumulative implantation volume and market share in China [3]. Group 2: Financial Status - As of June 30, 2025, Core Medical reported a cumulative undistributed profit of -367 million yuan, indicating it is still in a non-profitable state [4]. - The company aims to raise 1.217 billion yuan through its IPO to support product development, establish an industrialization base for artificial hearts, and enhance its marketing network and digital infrastructure [4]. Group 3: Investment and Market Position - Core Medical has undergone multiple rounds of financing, attracting investments from notable shareholders including Hillhouse Capital, Zhengxin Valley Investment Management, and others [6]. - The acceptance of Core Medical's IPO application under the fifth set of standards exemplifies the Shanghai Stock Exchange's efforts to broaden financing channels for innovative enterprises [5].

Core Viewpoint - Shenzhen Core Medical Technology Co., Ltd. has successfully had its IPO application accepted by the Shanghai Stock Exchange, marking it as the first innovative medical device company to be accepted under the new fifth set of listing standards for the Sci-Tech Innovation Board [1] Company Summary - Core Medical has received investments from multiple seasoned professional institutional investors, including Zhuhai Hillhouse Private Equity Fund Management Co., Ltd. and Shanghai Zhengxin Valley Investment Management Co., Ltd. [1] - This acceptance follows the case of Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd., making Core Medical the second company to recognize seasoned professional institutional investors in its Sci-Tech Innovation Board application [1] Industry Summary - The acceptance of Core Medical's IPO application is seen as a practical implementation of the "Sci-Tech-Capital" dual circulation in the innovative medical device sector [1] - It highlights the clear direction of the Sci-Tech Innovation Board in providing essential capital market support for high-quality technology enterprises that have significant R&D investments and long profit cycles [1]

Core Points - Shenzhen Core Medical Technology Co., Ltd. has become the first innovative medical device company to submit an IPO application under the reactivated fifth set of listing standards for the Sci-Tech Innovation Board [1][5] - The company focuses on providing comprehensive, innovative, and high-quality artificial heart products, addressing significant clinical needs in acute and chronic heart failure [3][4] - Core Medical has developed 5 implantable and 6 interventional artificial heart products, with one implantable product already commercialized and two interventional products in the registration approval stage [3][4] Financial Performance - Core Medical has not yet achieved profitability, with projected revenues of approximately 0, 16.55 million, 93.69 million, and 70.48 million CNY for the years 2022 to 2025, and net losses of approximately -178 million, -170 million, -132 million, and -72.75 million CNY for the same periods [4] - As of June 30, the company reported cumulative undistributed profits of -367 million CNY, indicating ongoing financial challenges [4] Market Position and Challenges - The artificial heart industry in China is still in its early development stages, with commercialization affected by factors such as clinical penetration, discipline development, surgical promotion, and patient payment capabilities [4] - Core Medical aims to become the first company to obtain approval for interventional artificial heart products in China, facing challenges in product promotion, market education, and brand building [4][5] IPO Details - The company plans to raise up to 1.217 billion CNY through its IPO, with funds allocated for research and development of circulatory support products, establishment of an artificial heart industrialization base, marketing network and digital construction, and working capital [5] - Core Medical meets the listing standards set forth in the Sci-Tech Innovation Board's regulations, which emphasize technological advancement and research capabilities over short-term financial metrics [5]